A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

NCT04297254 ·Status: COMPLETED ·Phase: PHASE4

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT02953743 ·Status: COMPLETED ·Phase: PHASE1

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

NCT01761266 ·Status: COMPLETED ·Phase: PHASE3

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

NCT02579616 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

NCT04241523 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

NCT04763408 ·Status: COMPLETED

Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer

NCT07298538 ·Status: ACTIVE_NOT_RECRUITING

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

NCT05920863 ·Status: RECRUITING ·Phase: PHASE2

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

NCT05807776 ·Status: COMPLETED ·Phase: PHASE2

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

NCT04642547 ·Status: COMPLETED ·Phase: NA

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

NCT03418922 ·Status: COMPLETED ·Phase: PHASE1

Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative

NCT05113186 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

NCT03801499 ·Status: WITHDRAWN ·Phase: PHASE2

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

NCT05312216 ·Status: UNKNOWN ·Phase: PHASE2

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

NCT07047586 ·Status: RECRUITING ·Phase: PHASE2

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

NCT04560751 ·Status: UNKNOWN

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT04053972 ·Status: UNKNOWN ·Phase: PHASE3

Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma

NCT01545804 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

NCT06519721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 ·Status: UNKNOWN ·Phase: NA

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT05608213 ·Status: RECRUITING ·Phase: PHASE3

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03433703 ·Status: TERMINATED ·Phase: PHASE2

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

NCT05250843 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593 ·Status: COMPLETED ·Phase: PHASE3